18F-FDG PET/CT for prediction of PD-L1 expression and tumor mutational burden in non-small cell lung cancer: biomarkers prediction models development and immunotherapy responses verification
SUL<sub>max</sub> is an independent predictor of both PD-L1-Pos and TMB-High in ADC. The clinical-SUL<sub>max</sub> combined models effectively predicted PD-L1-Pos and TMB-High status, as well as PD-L1-Neg and TMB-Low status in ADC, indicating the clinical utility in patient selection and immunotherapy response stratification.
Authors
- Jianming Ying (ORCID: https://orcid.org/0000-0003-2692-4052)
- Lei Guo (ORCID: https://orcid.org/0000-0003-1733-1802)
- Jing Li (ORCID: https://orcid.org/0000-0001-5173-0781)
- Wei Guo (ORCID: https://orcid.org/0000-0001-8302-8292)
- Ning Li (ORCID: https://orcid.org/0000-0003-2600-108X)
- Qian Zhang (ORCID: https://orcid.org/0000-0002-0808-8794)
- Pei Yuan
- Ning Wu (ORCID: https://orcid.org/0000-0001-6971-2995)
- Zewei Zhang (ORCID: https://orcid.org/0000-0003-2682-246X)
- Shuhang Wang (ORCID: https://orcid.org/0000-0001-5753-5936)
- Ying Liu (ORCID: https://orcid.org/0009-0003-0790-0327)
- Xiuli Tao
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- National Cancer Center (US)
- National Clinical Research (US)
Publication Details
- Journal
- Respiratory Research
- Published
- 2025-11-28
- DOI
- https://doi.org/10.1186/s12931-025-03430-3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00